NASDAQ NMS - GLOBAL MARKET · PRLD
+2.55% · +$0.1200 · Vol 121.8K
Live · updated 11:30:08 ET
Prelude Therapeutics Inc

Prelude Therapeutics Inc

Biotechnology
$4.82
Card
Relationship Map

Follow $PRLD

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $PRLD by email

Veridion Score

BETAMEDIUM CONF · 5 of 6 factors measuredMethodology
Sentiment absence reason unknown
PRLD
Prelude Therapeutics Inc
Mon Sep 21 · last completed session · daily score · 18h old
Upper range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

62/ 100
Veridion Score
Upper range · MEDIUM confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5 of 6 factors measured · Mon Sep 21 · last completed session · daily score · 18h old
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is PRLD moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading PRLD catalysts
About Prelude Therapeutics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2020
Employees
79
Country
US

Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$4.65
Day high
$4.85
Day low
$4.63
Previous close
$4.70
52W high
$6.63
-27.30% from high
52W low
$1.01
68% of range
Market cap
$375.1M
EPS
$-0.9400
Beta
0.65
Shares out
79.8M
Volume
121.8K
0.22× rel vol
Avg volume
545.5K
VWAP
$4.77
Price history computed in-house
1W
+6.64%
1M
-27.30%
3M
+12.88%
1Y
+377.23%
YTD
+66.21%
SMA 50 $5.01 · below
SMA 200 $3.78 · above
52W position 68%

PRLD overview

Veridion Score
62
Registered · 2026-09-21
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around PRLD.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading PRLD Form 4 filings
Public disclosures

Congress activity in PRLD

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for PRLD in the cached public ledger.

Federal contracts

PRLD contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for PRLD in this window.
Lobbying spend

PRLD lobbying filings, year to date.

Registered lobbying filings matched to Prelude Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for PRLD in this window.
Loading news for PRLD
Analyst ratings
Sovereign unlock shows live analyst consensus for PRLD.
Options
Sovereign unlock shows live options positioning for PRLD.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.